Résumé
Objectif
Population cible
Résultats
Bénéfices, risques et coûts
Données probantes
Méthodes de validation
Professionnels concernés
DÉCLARATIONS SOMMAIRES
- 1.Le cannabis est de plus en plus utilisé, et les femmes l’utilisent couramment pour des raisons récréatives et médicales (élevée).
- 2.L’utilisation de cannabis, en particulier des produits contenant du tétrahydrocannabinol, peut provoquer ou exacerber une psychose et aggraver une dépression (élevée).
- 3.Les résultats des études sur l’association entre le cannabis et l’anxiété sont contradictoires; par conséquent, cette association nécessite des recherches plus approfondies (élevée).
- 4.L’utilisation de cannabis, semblable à celle d’autres substances psychoactives, peut être associée à des comportements sexuels à risque élevé (faible).
- 5.Il n’existe aucunes données probantes indiquant que le cannabis altère l’efficacité des méthodes contraceptives (faible).
- 6.Les données probantes sont limitées concernant l’effet nocif de l’utilisation fréquente de cannabis sur la fertilité féminine (moyenne), mais l’utilisation fréquente peut diminuer la fertilité masculine (moyenne).
- 7.Il n’existe aucune donnée probante concernant l’utilisation de cannabis pour le traitement des symptômes périménopausiques (très faible).
- 8.Il n’existe aucune donnée probante indiquant que les produits de cannabis soulagent la douleur pelvienne chronique (faible).
RECOMMANDATIONS
- 1.Il faut dépister l’utilisation de cannabis chez les femmes au même titre que pour toute autre consommation de substances psychoactives (forte, moyenne) et amorcer une exploration plus poussée de ses effets (forte, moyenne).
- 2.Il est possible de dépister l’utilisation de cannabis à l’aide d’outils de dépistage appropriés (conditionnelle, moyenne).
- 3.Il y a lieu d’adopter une approche de soins tenant compte des traumatismes et de miser sur la réduction des méfaits lorsqu’il s’agit de poser des questions sur l’utilisation de cannabis (forte, faible).
- 4.Le fait qu’une femme utilise du cannabis ne devrait pas influencer son choix de méthode contraceptive (forte, moyenne).
- 5.Les couples doivent être informés que l’utilisation de cannabis semble nuire à la fertilité masculine et pourrait avoir un effet nocif sur la fertilité féminine (conditionnelle, moyenne).
- 6.On doit caractériser les troubles du sommeil se manifestant en période périménopausique et essayer d’autres modes de traitement avant que les femmes ne puissent envisager l’utilisation de produits de cannabis pour cette indication (forte, moyenne).
- 7.Il y a lieu d’informer les femmes du manque de données probantes sur l’utilisation de produits de cannabis pour traiter la douleur pelvienne chronique (forte, moyenne).
Mots clés
Abréviations:
Δ-9-THC ou THC (delta-9-tétrahydrocannabinol), 2-AG (2-arachidonoylglycérol), ARNm (acide ribonucléique messager), CB1 (cannabinoïde 1), CB2 (cannabinoïde 2), CBD (cannabidiol), CUDIT-R (test révisé de dépistage du trouble de l’usage du cannabis), CYP450 (cytochrome P450), DIBOT (dépistage, intervention brève et orientation vers le traitement), GABA (acide gamma-aminobutyrique), GnRH (gonadolibérine), TRH (thyréolibérine), TRPV1 (premier membre de la sous-famille V des récepteurs-canaux TRP sensibles aux vanilloïdes), TSPT (trouble de stress post-traumatique)Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Obstetrics and Gynaecology CanadaRéférences
- Canadian Cannabis Survey 2020: Summary.2020 (Disponible à :) (Consulté le 16 mai 2021)
- The Canadian Cannabis Survey Methodological Report.2017 (Disponible à :) (Consulté le 16 mai 2021)
- The Canadian Cannabis Survey 2018 Methodological Report.2018 (Disponible à :) (Consulté le 16 mai 2021)
- Canadian Cannabis Survey 2019 summary (Table 13).2019 (Disponible à :) (Consulté le 16 mai 2021)
- Summary of results: Canadian Student Tobacco, Alcohol and Drugs Survey 2018-2019. 2019.(Disponible à :) (Consulté le 16 mai 2021)
- Directive clinique n° 425b : Le cannabis aux différentes périodes de la vie des femmes — Partie 2 : Grossesse, période postnatale et allaitement.J Obstet Gynaecol Can. 2022; 44: 445-454
- Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis.Soc Sci Med. 2019; 233: 181-192
- Assessment of the Association of Cannabis on Female Sexual Function With the Female Sexual Function Index.Sex Med. 2020; 8: 699-708
- Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective.Neuropsychopharmacology. 2018; 43: 34-51
- Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment.Drug Alcohol Depend. 2004; 74: 265-272
- Telescoping of alcoholism in women alcoholics.Int J Addict. 1989; 24: 19-28
- Sex and gender interactions on the use and impact of recreational cannabis.Int J Environ Res Public Health. 2020; 17: 509
- The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.Br J Pharmacol. 2008; 153: 199-215
- Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System.Int J Mol Sci. 2018; 19
- Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.Lancet Neurol. 2019; 18: 504-512
- Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.Epilepsia. 2014; 55: 791-802
- Human cannabinoid pharmacokinetics.Chem Biodivers. 2007; 4: 1770-1804
- Pharmacokinetics and pharmacodynamics of cannabinoids.Clin Pharmacokinet. 2003; 42: 327-360
- Subjective and physiological effects after controlled Sativex and oral THC administration.Clin Pharmacol Ther. 2011; 89: 400-407
- Clearing the smoke on cannabis: Edible cannabis products, cannabis extracts and cannabis topicals. Canadian Centre on Substance Use and Addiction [Internet].2020 (Disponible à :) (Consulté le 4 octobre 2021)
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed). Arlington, VA2013.
- Clearing the Smoke on Cannabis: Cannabis Use and Driving - An Update. Canadian Centre on Substance Use and Addiction [Internet].2019 (Disponible à :) (Consulté le 4 octobre 2021)
- Cannabis poisoning.2019 (Disponible à :) (Consulté le 4 octobre 2021)
- Meta-analysis of the association between the level of cannabis use and risk of psychosis.Schizophr Bull. 2016; 42: 1262-1269
- Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review.Brain Sci. 2020; 10: 1-17
- Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis.Lancet Psychiatry. 2016; 3: 215-225
- Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: A systematic review and meta-analysis.JAMA Psychiatry. 2019; 76: 426-434
- Cannabis use during adolescence and the occurrence of depression, suicidality and anxiety disorder across adulthood: Findings from a longitudinal cohort study over 30 years.J Affect Disord. 2020; 272: 98-103
- Associations of Suicidality Trends With Cannabis Use as a Function of Sex and Depression Status.JAMA Network Open. 2021; 4e2113025-e
- A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies.BMC Psychiatry. 2014; 14: 136
- The association between cannabis use and anxiety disorders: Results from a population-based representative sample.Eur Neuropsychopharmacol. 2016; 26: 493-505
- The role of cannabis in treating anxiety: an update.Curr Opin Psychiatry. 2020; 33: 1-7
- The relationship between cannabis use disorders and social anxiety disorder in the National Epidemiological Study of Alcohol and Related Conditions (NESARC).Drug Alcohol Depend. 2012; 124: 128-134
- Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample.Psychol Addict Behav. 2015; 29: 633-638
- Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning Canadian Centre on Substance Use and Addiction [Internet].2019 (Disponible à :) (Consulté le 4 octobre 2021)
- Clearing the smoke on cannabis: Respiratory and cardiovascular effects of cannabis smoking. Canadian Centre on Substance Use and Addiction [Internet].2020 (Disponible à :) (Consulté le 4 octobre 2021)
- Adolescent cannabis use and repeated voluntary unprotected sex in women.Addiction. 2016; 111: 2012-2020
- Association between cannabis use and sexual risk behavior among young heterosexual adults.AIDS Behav. 2006; 10: 599-605
- Marijuana use and sex with multiple partners among lesbian, gay and bisexual youth: results from a national sample.BMC Public Health. 2017; 17: 19
- Cannabis use and sexual health.J Sex Med. 2010; 7: 787-793
- Cannabis, risk and normalisation: evidence from a Canadian study of socially integrated, adult cannabis users.Health Risk Soc. 2014; 16: 210-226
- Gender norms, roles and relations and cannabis-use patterns: A scoping review.Int J Environ Res Public Health. 2020; 17: 947
- Chronic pain patients' perspectives of medical cannabis.Pain. 2017; 158: 1373-1379
- Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study.Harm Reduct J. 2013; 10: 2
- Perceived support for medical cannabis use among approved medical cannabis users in Canada.Drug Alcohol Rev. 2018; 37: 627-636
- The majority of Canadians don't plan to consume legal cannabis, Canadian insights into cannabis legalization: CCSA September OMNI Survey Summary - FINAL.2018 (Disponible à :) (Consulté le 4 octobre 2021)
- An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R).Drug Alcohol Depend. 2010; 110: 137-143
- Screening Women for At-Risk Alcohol Use: An Introduction to Screening, Brief Intervention, and Referral to Treatment (SBIRT) in Women's Health.J Midwifery Womens Health. 2017; 62: 746-754
- Screening, Brief Intervention and Referral to Treatment: implications of SAMHSA's SBIRT initiative for substance abuse policy and practice.Addiction. 2017; 112: 110-117
- Interventions delivered during antenatal care to reduce alcohol consumption during pregnancy: A systematic review.Addict Res Theory. 2011; 19: 235-250
- Motiviational Inteviewing: Helping People Change.3rd ed. Guilford Press, New York2012
- Single-session motivational intervention to decrease alcohol use during pregnancy.J Subst Abuse Treat. 2014; 47: 10-19
- Motivational interviewing: a systematic review and meta-analysis.Br J Gen Pract. 2005; 55: 305-312
- Trauma-informed Care (The Essentials of … Series).2014 (Disponible à :) (Consulté le 4 octobre 2021)
- Trauma-informed care: Better care for everyone.Can Fam Physician. 2018; 64: 170-172
- Adverse childhood experiences are associated with at-risk drinking, cannabis and illicit drug use in females but not males: an Emergency Department study.Am J Drug Alcohol Abuse. 2020; : 1-10
- Harm Reduction Policies and Programs Involved for Persons Involved in the Criminal Justice System.2005 (Disponible à :) (Consulté le 4 octobre 2021)
Centers for Disease Control and Prevention. Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products.
- Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.Am J Public Health. 2017; 107: e1-e12
- Marijuana, the Endocannabinoid System and the Female Reproductive System.Yale J Biol Med. 2016; 89: 175-191
- Overlapping molecular pathways between cannabinoid receptors type 1 and 2 and estrogens/androgens on the periphery and their involvement in the pathogenesis of common diseases (Review).Int J Mol Med. 2016; 38: 1642-1651
- The role of the endocannabinoid system in female reproductive tissues.J Ovarian Res. 2019; 12: 3
- Effects of delta 9-tetraphydrocannabinol administration on gonadal steroidogenic activity in vivo.Fertil Steril. 1979; 32: 576-582
- Tolerance develops to the disruptive effects of delta 9-tetrahydrocannabinol on primate menstrual cycle.Science. 1983; 219: 1453-1455
- Lifestyle and reproductive factors associated with follicular phase length.J Womens Health (Larchmt). 2007; 16: 1340-1347
- Menstrual Cycle in Women Who Co-use Marijuana and Tobacco.J Addict Med. 2018; 12: 207-211
- The (endo)cannabinoid signaling in female reproduction: What are the latest advances?.Prog Lipid Res. 2020; 77: 101019
- The grass isn't always greener: The effects of cannabis on embryological development.BMC Pharmacol Toxicol. 2016; 17: 45
- Marijuana-derived cannabinoids inhibit uterine endometrial stromal cell decidualization and compromise trophoblast-endometrium cross-talk.Reprod Toxicol. 2019; 87: 100-107
- Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling.Reprod Toxicol. 2020; 93: 75-82
- Cannabinoids and Cytochrome P450 Interactions.Curr Drug Metab. 2016; 17: 206-226
- Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone.Drug Metab Dispos. 2013; 41: 263-269
- Canadian Contraception Consensus (Part 1 of 4).J Obstet Gynaecol Can. 2015; 37: 936-942
- The use of cannabis and perceptions of its effect on fertility among infertility patients.Hum Reprod Open. 2020; 2020: hoz041
- Endocannabinoids and Reproductive Events in Health and Disease.Handb Exp Pharmacol. 2015; 231: 341-365
- Cannabis use while trying to conceive: a prospective cohort study evaluating associations with fecundability, live birth and pregnancy loss.Hum Reprod. 2021; 36: 1405-1415
- Cannabis and Male Fertility: A Systematic Review.J Urol. 2019; 202: 674-681
- Chronic cannabidiol exposure promotes functional impairment in sexual behavior and fertility of male mice.Reprod Toxicol. 2018; 81: 34-40
- Effects of Cannabinoids on Female Sexual Function.Sex Med Rev. 2020; 8: 18-27
- The Relationship between Marijuana Use Prior to Sex and Sexual Function in Women.Sex Med. 2019; 7: 192-197
- Male-female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function.Horm Behav. 2010; 58: 91-99
- The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease.Int J Mol Sci. 2020; 21
- The Impact of Perioperative Cannabis Use: A Narrative Scoping Review.Cannabis Cannabinoid Res. 2019; 4: 219-230
- Cannabis and symptoms of PMS and PMDD.Addict Res Theory. 2017; 25: 383-389
- Cannabis, Cannabinoids, and Sleep: a Review of the Literature.Curr Psychiatry Rep. 2017; 19: 23
- What Every Gynecologist Should Know About Perimenopause.Clin Obstet Gynecol. 2020; 63: 720-734
- Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.Lancet Psychiatry. 2019; 6: 995-1010
- Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors.Nat Med. 2005; 11: 774-779
- Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies.Pain. 2018; 159: 1932-1954
- The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.Neuropsychopharmacology. 2018; 43: 52-79
- The role of the endocannabinoid system in aetiopathogenesis of endometriosis: A potential therapeutic target.Eur J Obstet Gynecol Reprod Biol. 2020; 244: 87-94
- Cannabis Use, a Self-Management Strategy Among Australian Women With Endometriosis: Results From a National Online Survey.J Obstet Gynaecol Can. 2020; 42: 256-261
- Recreational Cannabis Use Before and After Legalization in Women With Pelvic Pain.Obstet Gynecol. 2021; 137: 91-99
- Expression of Cannabinoid Receptors in Myometrium and its Correlation With Dysmenorrhea in Adenomyosis.Reprod Sci. 2019; 26: 1618-1625
- Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis.Biomed Res Int. 2019; 2019: 5468954
- Tetrahydrocannabinol Reduces Hapten-Driven Mast Cell Accumulation and Persistent Tactile Sensitivity in Mouse Model of Allergen-Provoked Localized Vulvodynia.Int J Mol Sci. 2019; 20
- Marijuana, lower urinary tract symptoms, and pain in the urologic patient.Urology. 2020;
- Cannabis withdrawal in the United States: results from NESARC.J Clin Psychiatry. 2008; 69: 1354-1363
- Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers.Drug Alcohol Depend. 2010; 111: 120-127
- The current state of pharmacological treatments for cannabis use disorder and withdrawal.Neuropsychopharmacology. 2018; 43: 173-194
- Perioperative Pain and Addiction Interdisciplinary Network (PAIN): consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users by a modified Delphi process.Br J Anaesth. 2021; 126: 304-318
- A review of human studies assessing cannabidiol's (CBD) therapeutic actions and potential.J Clin Pharmacol. 2019; 59: 923-934
Références
- Free and glucuronide whole blood cannabinoids' pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: Identification of recent cannabis intake.Clin Chem. 2016; 62: 1579-1592
- Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: A crossover trial.JAMA Netw Open. 2018; 1e184841
- Pharmacokinetics and pharmacodynamics of cannabinoids.Clin Pharmacokinet. 2003; 42: 327-360
- Human cannabinoid pharmacokinetics.Chem Biodivers. 2007; 4: 1770-1804
- Urinary excretion profile of 11-nor-9-carboxy-delta9-tetrahydrocannabinol (thccooh) following smoked and vaporized cannabis administration in infrequent cannabis users.J Anal Toxicol. 2020; 44: 1-14
- Sex differences in the acute effects of smoked cannabis: Evidence from a human laboratory study of young adults.Psychopharmacology (Berl). 2020; 237: 305-316
- Pharmacodynamic effects of vaporized and oral cannabidiol (cbd) and vaporized cbd-dominant cannabis in infrequent cannabis users.Drug Alcohol Depend. 2020; 211: 107937
- Cannabis vaping: Understanding the health risks of a rapidly emerging trend.Paediatrics & Child Health. 2020; 25: S16-S20
- A systematic review on the pharmacokinetics of cannabidiol in humans.Front Pharmacol. 2018; 9: 1365
- Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes.J Anal Toxicol. 2017; 41: 83-99
- Subjective and physiological effects after controlled sativex and oral thc administration.Clin Pharmacol Ther. 2011; 89: 400-407
Article info
Publication history
Footnotes
Le présent document correspond au consensus clinique et scientifique en vigueur au moment de sa publication et est sujet à changement. Les renseignements qu’il contient ne doivent pas être considérés comme les seuls traitements ou les seules interventions applicables. Les établissements locaux peuvent modifier les recommandations. La SOGC conseille toutefois aux établissements de bien documenter de telles modifications.
Consentement éclairé : Chaque personne a le droit et la responsabilité de prendre des décisions éclairées relativement aux soins qu’elle reçoit en partenariat avec ses fournisseurs de soins de santé. Pour aider les patientes à faire un choix éclairé, il faut leur fournir un soutien et des renseignements fondés sur des données probantes, adaptés à leur culture et personnalisés. Il faut tenir compte des valeurs, croyances et besoins de chaque patiente en fonction de ses circonstances personnelles et respecter la décision finale de la patiente quant aux options de soins et de traitements.
Langue et inclusion : La SOGC reconnaît l’importance d’être pleinement inclusif. Par conséquent, les principes de rédaction épicène seront utilisés dans la mesure du possible lorsque le contexte s’y prête. Autrement, la SOGC continue d’utiliser l’écriture genrée en raison de sa mission de faire progresser la santé des femmes. La SOGC reconnaît et respecte les droits de chaque personne à qui le présent contenu pourrait s’appliquer, notamment les personnes transgenres, non binaires ou intersexes. La SOGC encourage les fournisseurs de soins de santé à s’engager dans une conversation respectueuse avec chaque patiente et patient relativement à son identité de genre et au pronom de genre de son choix, ainsi qu’à appliquer les présentes directives comme il convient pour répondre aux besoins de chaque personne.
Identification
Copyright
ScienceDirect
Access this article on ScienceDirectLinked Article
- Guideline No. 425a: Cannabis Use Throughout Women’s Lifespans – Part 1: Fertility, Contraception, Menopause, and Pelvic PainJournal of Obstetrics and Gynaecology Canada Vol. 44Issue 4
- PreviewTo provide health care providers with the best evidence on cannabis use with respect to women’s health. Areas of focus include general patterns of cannabis use as well as safety of use; care for women who use cannabis; stigma; screening, brief intervention, and referral to treatment; impact on hormonal regulation; reproductive health, including contraception and fertility; sexual function; effects on perimenopausal and menopausal symptoms; and use in chronic pelvic pain syndromes.
- Full-Text
- Preview